List view / Grid view
24 February 2016 | By Victoria White
At Week 48 of the study, the F/TAF-based regimens were found to be statistically non-inferior to the F/TDF-based regimens in HIV-1 infected adult patients...
1 February 2016 | By Victoria White
The application is based on the results of two large placebo-controlled trials of Truvada for PrEP, the Pre-Exposure Prophylaxis Initiative (iPrEX) and Partners PrEP...
6 January 2016 | By Victoria White
The studies demonstrated that TAF was non-inferior to Gilead’s Viread (tenofovir disoproxil fumarate, TDF) based on the percentage of patients with HBV DNA levels below 29 IU/mL at 48 weeks of therapy...
23 November 2015 | By
Genvoya is the first TAF-based regimen to receive marketing authorisation in the EU...
13 November 2015 | By Victoria White
The FDA has approved Harvoni for expanded use in patients with genotype 4, 5 and 6 chronic HCV infection and in patients co-infected with HIV...
6 November 2015 | By Victoria White
Genvoya contains a new form of tenofovir that has not been previously approved...
22 October 2015 | By Victoria White
Genvoya was found to be statistically non-inferior to Stribild based on percentages of patients with HIV-1 RNA levels less than 50 copies/mL...
22 October 2015 | By Victoria White
GS-5734 was discovered as part of Gilead’s programme to screen compounds in its libraries for activity against a range of potential emerging viruses, including Ebola...
5 October 2015 | By Victoria White
The combination is approved to reduce the risks of disease progression and hospitalisation for worsening PAH, and to improve exercise ability...
25 September 2015 | By Victoria White
The CHMP’s recommendation will now be reviewed by the European Commission. If approved, Genvoya would be Gilead’s first single tablet regimen to contain TAF...
24 September 2015 | By Victoria White
Idelalisib has been recommended in combination with rituximab for adults with chronic lymphocytic leukaemia (CLL) who have relapsed early...
21 August 2015 | By Victoria White
An MAA for an investigational regimen that combines emtricitabine, tenofovir alafenamide and rilpivirine (R/F/TAF) has been fully validated by the EMA...
22 July 2015 | By Victoria White
Detailed 48-week data from a Phase 3 study evaluating E/C/F/TAF regimen in patients with HIV-1 was presented at the 8th IAS Conference...
16 July 2015 | By Victoria White
The EC has approved Evotaz tablets in combination with other antiretroviral agents for the treatment of HIV-1 infected adults...
2 July 2015 | By Victoria White
Gilead Sciences has submitted a NDA to the FDA for an investigational, once-daily single tablet regimen for the treatment of HIV-1 infection...
